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Abstract Hyperkalemia is a potentially life-threatening
condition in which serum potassium exceeds 5.5 mmol/l.
It can be caused by reduced renal excretion, excessive
intake or leakage of potassium from the intracellular space.
In addition to acute and chronic renal failure, hypoaldoster-
onism, and massive tissue breakdown as in rhabdomyol-
ysis, are typical conditions leading to hyperkalemia.
Symptoms are non-specific and predominantly related to
muscular or cardiac dysfunction. Treatment has to be
initiated immediately using different therapeutic strategies
to increase potassium shift into the intracellular space or to
increase elimination, together with reduction of intake.
Knowledge of the physiological mechanisms of potassium
handling is essential in understanding the causes of hyper-
kalemia as well as its treatment. This article reviews the
pathomechanisms leading to hyperkalemic states, its symp-
toms, and different treatment options.
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Introduction
Potassium is the most abundant intracellular cation (100-
150 mmol/l) and is critical in many physiological functions.
Absorption of potassium from the gastrointestinal tract is
rapid and usually complete. Depending on diet, the normal
daily intake can vary. Common potassium-rich foods
include fruits, potatoes, beans, and grains; in contrast,
high-fat diets usually contain low amounts of potassium
(Table 1). Low extracellular potassium concentrations of
3.5–5.5 mmol/l are maintained by distinct renal and
extrarenal mechanisms. The major key effector is the
energy-consuming enzyme Na
+/K
+-ATPase, located in the
plasma membrane of cells, which pumps Na
+ out of and K
+
into the cell in a 3:2 ratio (3Na
+:2K
+). The Na
+/K
+-ATPase
helps to maintain the resting potential and avail transport,
and helps to regulate cellular volume as well as intracellular
calcium content. Extrarenal mechanisms are able to shift K
+
from extra- to intracellularly, but the excretion of potassium
mainly occurs in the kidneys. Renal adaptive mechanisms
allow the kidneys to maintain potassium homeostasis until
the glomerular filtration rate (GFR) drops to less than
15 ml/min/1.73 m
2. Approximately 10% of the daily
potassium intake is cleared via the gastrointestinal tract. In
the presence of renal failure, the proportion of potassium
excreted through the gut can increase, but is subject to high
inter-individual variability [1].
Renal mechanisms of potassium handling
Handling of potassium in the nephron depends on passive
and active mechanisms. Potassium is filtered in the
glomerulus and almost completely reabsorbed in the
proximal tubule and the loop of Henle. Excretion mainly
occurs in the cortical collecting duct [2]. It should be noted,
however, that reabsorption and secretion of potassium occur
simultaneously, and that many modulators are important,
such as diet, adrenal steroids, and acid-base balance.
Approximately 60-75% of the filtered potassium is
reabsorbed in the proximal tubule (PT) by diffusion and
solvent drag, mainly coupled to Na
+ transport. The
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The Na
+/H
+ antiporter is the most important system in this
respect, and paracellular shunt-pathways are also present.
Diffusion is driven by lumen-negative electrical potential
created by the Na
+/K
+-ATPase in the second half of the
proximal tubule, which creates high Cl
- concentrations in
the lumen.
Approximately 15-20% of the filtered potassium is
reabsorbed in the thick ascending limb of the Loop of
Henle (TAL). Several co-transporters and ion channels are
involved in the complex regulatory system of potassium
reabsorption. The best characterized is the Na-K-2Cl
cotransporter (NKCC2), which transports potassium out of
the tubular fluid and is inhibited by loop diuretics
(furosemide). Some of the potassium recycles back into
the tubular fluid via K channel ROMK (renal outer
medullary K
+channel) in the apical membrane, but a
fraction of it moves into the interstitial fluid. The TAL
establishes the potential for countercurrent trapping of
potassium in the medulla in a manner similar to that for
Na
+ and NHþ
4 . Basolateral transporters include a KCl
cotransporter.
The distal convoluted tubule (DCT) is the site of the
apical sodium chloride cotransporter (NCCT), which is
blocked by thiazides [3]. It modulates excretion of not only
potassium but also calcium and magnesium. NCCT and
ROMK channels seem to regulate potassium excretion
under the influence of serine/threonine kinases, especially
lysine-deficient protein kinase-1 and 4 (WNK-1 and WNK-
4) [4]. There is evidence that the calcium-sensing receptor
(CaSR) influences the renal ion transport, amongst others
by inhibiting the activity of ROMK [5].
At least two circulating factors are required for the
regulation of renal K
+ secretion by the cortical collecting
duct (CCD), the main site of renal potassium excretion,
aldosterone, and a second as yet unidentified factor that
increases the number of conducting K
+ channels [6].
Aldosterone as key regulator of renal potassium homeo-
stasis binds to the nuclear mineralocorticoid receptor (MR)
within the distal tubule and the principal cells in the CCD.
It activates the basolateral Na
+/K
+-ATPase, thereby increas-
ing Na
+ and water reabsorption into the blood and secretion
of K
+ into the urine. Aldosterone also upregulates the
amiloride sensitive sodium channels (ENaCs) in the apical
membrane of CCD and stimulates H
+ secretion by
intercalated CCD cells, thereby influencing acid/base
balance [7].
K
+ secretion can be partially counteracted by reabsorp-
tion by the intercalated cells in the cortical and outer
medullary collecting tubules [8, 9]. Vasopressin increases
K
+ excretion in the medullary collecting duct while
promoting antidiuresis [10].
Extrarenal regulatory mechanisms of potassium
metabolism
Acid-base balance can affect the balance between cellular
and extracellular potassium concentration. Acidosis
increases the plasma K
+ concentration by inducing a net
shift of K
+ from the cellular to the extracellular compart-
ment in exchange with H
+, also leading to a reduced tubular
secretion of potassium.
Insulin is important in preventing a large change in
extracellular fluid (ECF) K
+ concentration as it increases
potassium uptake into liver and muscle cells by stimulating
Na
+/K
+-ATPase. Large increases in ECF K
+ concentration
(>1-1.5 mmol/l) stimulate insulin secretion, which pro-
motes shift of excess K
+ into the intracellular compartment.
Lastly, catecholamines (adrenaline, noradrenaline, dopa-
mine) binding to beta-2 receptors on muscle cells stimulate
the Na
+/K
+-ATPase and cause increased K
+ shift into cells.
Pathogenesis of hyperkalemia
Hyperkalemia may result from an increase in total body
potassium secondary to imbalance of intake vs. excretion
or from maldistribution between intra- and extracellular
space.
Table 1 Potassium content of selected foods
Foods and drinks Potassium content (mmol)
1 small banana (85 g) 8.6
Blueberries (100 g) 1.9
White mushrooms (75 g) 8.1
Broccoli, cooked (75 g) 5.8
Green beans, cooked (75 g) 3.9
Onions, cooked (75 g) 1.5
French fries (150 g) 17.7
Parboiled rice (150 g) 2.2
Spaghetti, without egg (150 g) 2.3
Orange juice (200 ml) 7.9
Milk, full fat (200 ml) 7.7
Coca Cola (200 ml) 0.1
Potato crisps (20 g) 5.1
Milk chocolate bar (20 g) 2.4
White chocolate (20 g) 1.8
Wine gums (20 g) 1.8
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In patients with unimpaired renal function and intact other
regulatory mechanisms, large amounts of potassium are
needed to achieve hyperkalemia [11]. Whereas in patients
with impaired renal function, especially when GFR is
<15 ml/min, a slight increase in potassium intake can cause
severe hyperkalemia.
Impaired elimination of potassium
1) Renal insufficiency acute or chronic: reduced GFR
(especially <15 ml/min/1.73 m
2) with low urine flow
(and therefore low sodium delivery to the distal tubule)
lead to decreased renal excretion of potassium.
2) Medications interfering with urinary potassium excretion
(also see Table 2): of special clinical relevance are
potassium-sparing diuretics (amiloride or spironolactone),
cyclosporine, trimetoprim [12]. Non-steroidal anti-inflam-
matory drugs (NSAIDs; ibuprofen, naproxen) and ACEI
(angiotensin converting enzyme inhibitors) as well as
angiotensin receptor inhibitors can cause a decrease in
aldosterone and GFR and thereby lead to hyperkalemia
[13]. Combined treatment with spironolactone and ACE
inhibitors, especially in patients with renal impairment or
heart failure, has to be monitored very carefully.
3) Hypoaldosteronism may either be primary (e.g. M.
Addison) or secondary (e.g. chronic renal failure),
resulting in hyperkalemia accompanied by urinary salt
wasting, leading to volume depletion and hypotension
[14, 15]. A similar picture can be seen in patients with
obstructive uropathy and renal tubular acidosis [16,
17].
4) Pseudohypoaldosteronism (PHA) refers to a heteroge-
neous group of disorders of electrolyte metabolism
characterized by hyperkalemia, metabolic acidosis,
and normal GRF [18]. PHA type I caused by autosomal
dominant mutations in the human mineralocorticoid
receptor (MR) gene is limited to the kidneys. PHA type
I secondary to loss of function mutations of the ENaC
not only affects the kidney but also the lungs, colon,
and sweat and salivary glands. PHA-II (also known as
Gordon’s syndrome) is a rare familial renal tubular
defect caused by loss of function mutations in WNK1
or WNK4 [19]. Gordon’s syndrome is characterized by
volume expansion, suppressed renin, and reduced
mineralocorticoid-induced renal clearance of potassium
leading to hypertension and hyperkalemia, and hyper-
chloremic acidosis with normal glomerular filtration
rate [20].
5) Congenital adrenal hyperplasia (CAH): caused by
mutation or deletion of any of the genes that code for
enzymes involved in cortisol or aldosterone synthesis
Table 2 Drugs inducing hyperkalemia
Drug Mechanisms
Amiloride Blocking sodium channels of luminal membrane of principal cells
Spironolactone Mineralocorticoid receptor antagonist (competing with aldosterone)
Inhibition of adrenal aldosterone biosynthesis
Cyclosporine, Tacrolimus Inhibition of adrenal aldosterone biosynthesis
Induction of chloride channel shunt
Increasing potassium efflux from cells
Trimetoprim, Pentamidine Blocking of sodium channels in the luminal membrane of principal cells
NSAIDs Induction of hyporeninemic hypoaldosteronism through inhibiting renal prostaglandin synthesis
ACE inhibitors, Angiotensin-II
receptor antagonists
Reduction in adrenal aldosterone biosynthesis through interrupting renin-aldosterone axis
Reduction in effective glomerular filtration rate
Beta blockers Inhibiting renin secretion
Decrease in cellular potassium uptake
Calcium channels blockers
(Nifedipine, Amlodipine)
Inhibition of adrenal aldosterone biosynthesis
Reduction in aldosterone secretion
Succinylcholine Leakage of potassium out of cells through depolarization of cell membranes
Digoxin Inhibition of Na
+/K
+-ATPase
Heparin Inhibition of adrenal aldosterone biosynthesis
Decreasing number and affinity of angiotensin-II receptors
Mannitol “Solvent drag phenomena” whereby potassium shifts out of cells due to the body’s attempt to maintain
isotonicity while undergoing a hypertonic infusion
NSAIDs non-steroidal anti-inflammatory drugs
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to 21-hydroxylase deficiency [21]. The particular
phenotype and degree of hyperkalemia depends on
the sex of the individual, the location of the block in
synthesis, and the severity of the genetic deletion or
mutation.
6) Congestive heart failure: reduced renal function and
treatment with drugs interfering with renal potassium
excretion often lead to hyperkalemia [14, 22].
7) Constipation: enteral elimination of potassium can be
decreased and therefore lead to hyperkalemia, which
again might lead to reduced bowel movements.
Patients with bowel emptying problems secondary
to myelodysplasia or VACTERL-association are at
special risk.
Increased shift of potassium from intra to extracellular
space
1) Acidosis: Mineral acidosis is more likely to cause a
shift of potassium from intracellular space into extra-
cellular space than organic acidosis.
2) Diabetes mellitus: reduced insulin levels lead to
accumulation of potassium in the extracellular space
[23].
3) Acute increase in osmolality secondary to hyperglyce-
mia or mannitol infusion causes potassium to exit from
cells [24].
4) Acute cell-tissue breakdown: if extensive cell damage
occurs, intracellular potassium is released into extra-
cellular space. This can be the case in patients with
rhabdomyolysis, tumorlyis, hemolysis, or after massive
transfusion.
5) Drugs (also see Table 2): digoxin and beta-blockers
(especially non-selective ones) inhibit the basolateral
Na
+/K
+-ATPase [25]. Succinylcholine, especially when
given to patients with burn injuries, immobilization, or
inflammation [26].
6) Hyperkalemic periodic paralysis: rare condition with
mutations of the muscular sodium channel, resulting in
paralytic episodes associated with elevated K
+ levels [27].
Diagnosis of hyperkalemia
Hyperkalemia can be classified according to serum potas-
sium into mild (5.5–6.5 mmol/l), moderate (6.5–7.5 mmol/
l) and severe (>7.5 mmol/l) hyperkalemia.
Hyperkalemia is rarely associated with symptoms,
occasionally patients complain of palpitations, nausea,
muscle pain, or paresthesia. However, moderate and
especially severe hyperkalemia can lead to disturbances
of cardiac rhythm, which can be fatal [28, 29]. Electro-
cardiography (ECG) monitoring is mandatory in patients
with serum potassium >6.5 mmol/l. ECG changes may
present as non-specific repolarization abnormalities,
“peaked” T-waves, and QRS widening as well as depression
of ST-segment.
Examination and investigations should be systematic and
always include assessment of cardiac function, kidneys, and
urinary tract as well as hydration status and neurological
evaluation. Laboratory workup should be comprehensive,
especially if the underlying cause is unknown (Table 3).
Figure 1 gives a diagnostic algorithm based on GFR and
aldosterone levels.
Pseudohyperkalemia
If elevated serum potassium is found in an asymptomatic
patient with no apparent cause, factitious hyperkalemia
should be considered. This results from leakage of
potassium from the intracellular space during or after blood
sampling. In these cases, elevation of serum potassium
concentration does not reflect the level of serum potassium
in vivo and no treatment is needed. Especially in pediatrics,
mechanical hemolysis can occur during difficult blood
draws, and even more in samples with lymphocytosis or
thrombocytosis. Especially when capillary samples are
taken, excess alcohol on the skin should be avoided, as it
is the primary cause of the hemolysis in this process.
Correction factors have been discussed, but blood usually
has to be drawn again [30].
Management of hyperkalemia
Therapeutic strategies should be individualized, taking into
account the degree and the cause of hyperkalemia.
Management should not only rely on ECG changes but be
guided by the clinical scenario and serial potassium
measurements [29, 31]. Treatment has to be more aggres-
sive the higher and the faster the rise of the potassium level,
and the greater the evidence of toxicity (ECG changes).
Most medical therapies for hyperkalemia provide only
transitory improvement by shifting K
+ into intracellular
space without actually eliminating potassium. These thera-
peutic measures often are sufficient in acute hyperkalemia
in patients without significant renal impairment, where an
increase in renal potassium excretion can be achieved. In
patients with moderate to severe hyperkalemia (>6.5 mmol/l),
especially those with renal impairment, all therapeutic
strategies including renal replacement therapy may be
necessary [32].
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neously. Additionally, if unknown, the cause of hyperkalemia
has to be determined to prevent future episodes. Dosage and
side-effects of drugs are given in Table 4.
Step 1: Evaluate patient for potential toxicities and initiate
ECG monitoring
& If patient has severe hyperkalemia or shows ECG
changes, transfer to intensive care unit (ICU)
immediately.
& Ca-Gluconate 10% can be used in patients with
cardiac symptoms to stabilize membrane potential
and positively influence bradycardia and ECG
changes. Contraindications: digoxin-intoxication,
hypercalcemic states.
Step 2: Identify and immediately eliminate sources of
potassium intake
& Review prescriptions and stop oral or parenteral
potassium supplements.
& Stop all drugs that might cause or aggravate
hyperkalemia.
& Input of dieticians might be needed to identify
potassium-rich foods (check for “special diets”),
especially in patients with chronic renal failure.
Step 3: Increase potassium shift from extra- to intracellu-
lar space
& Dextrose and/or insulin infusion. An effect can
often be seen immediately but response remains
unpredictable. Close electrolyte and blood glucose
monitoring is needed, hypoglycemia being the main
side-effect. Aim to maintain blood glucose 10-
15 mmol/l.
& Beta-adrenergic agonists (salbutamol, reproterol)
stimulate potassium to shift from extra to intracellular
space via Na
+/K
+-ATPase as described above. Salbu-
tamol can be applied via nebulizer or given intrave-
nously. If given iv, the lowering effect of salbutamol
is quite predictable with a mean decrease of 1.6-
1.7 mmol/l after 2 h [33]. It can cause tachycardia.
Salbutamol has been shown to be safe and even
superior to rectal cation-exchange resin in non-
oliguric preterms with hyperkalemia [34].
Table 3 Laboratory investigations in hyperkalemia
Differential diagnosis
Blood test
Full blood count Hemolytic anemia
HUS
Thrombocytosis
Infection & sepsis
Blood gas analysis Acidosis
Serum osmolality Calculation of TTKG
Creatinine, urea Acute and chronic renal insufficiency
CK Rhabdomyolysis
ALT Hemolysis, tumor lysis
LDH Hemolysis, tumor lysis
Glucose, glycosylated hemoglobin Diabetes mellitus
Renin, angiotensin, aldosterone Hyporeninemic hypoaldosteronism, pseudohypoaldosteronism
Cortisol, 11-beta hydroxylase or 21-hydroxylase or
17-OH progesterone in plasma
Reduced enzyme activities in congenital adrenal hyperplasia
Urine test
Potassium, sodium, creatinine Salt wasting
Albumin Proteinuria
TTKG TTKG expected to be high (usually >10) in hyperkalemia when renal response is intact.
An inappropriately low TTKG in a hyperkalemic patient suggests hypoaldosteronism or
a renal tubule defect [39]
(S Osm * U Potassium) / (S Potassium * U Osm)
Index of potassium secretory activity in the distal
tubule
Test is most useful in distinguishing patients who have mineralocorticoid deficiency
versus resistance by observing a change in TTKG values after administration of
mineralocorticoid: increase in TTKG in mineralocorticoid-deficient but not aldosterone
resistant states
Only valid when urine osmolality >300 and urine
sodium >25 mmol/l
TTKG Transtubular potassium gradient, CK creatinine kinase, ALT alanine transaminase, LDH lactate dehydrogenase
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Drug Dose Rapidity of
action
Side-effects/complications
Dextrose/insulin 2.5-5 ml/kg/h 20% dextrose (0.5-1 g/kg/h)
with insulin 0.2 units for every gram of
glucose administered
Fast Hypoglycemia, hyperosmolarity, volume
overload
Salbutamol (ten drops of standard
sabutamol inhalation solution
contain 2.5 mg)
iv: 4-5 μg/kg in 15 ml of 5% dextrose/
water, short infusion over 15 min
Fast Tachycardia
Nebulized: 2.5 mg if <25 kg and 5 mg if
>25 kg
Sodium bicarbonate 8.4% 1-2 mmol/kg over 30-60 min or calculated
on base-deficit
Intermediate Sodium load (hypertension)
Furosemide 1-2 mg/kg Intermediate Ototoxicity, nephrotoxicity
Ion exchange resins Given p.o. or p.r. calcium resonium 1 g/kg
sodium resonium 1 g/kg
Slow p.o.: nausea, constipation or even paralytic
ileus. Diarrhea if preparations come
premixed with sorbitol
p.r.: cecal perforation
Ca-Gluconate 10% 0.5–1 ml/kg over 5-10 min, preferably ad-
ministered via central venous access
Hypercalcemia, tissue necrosis
NOTE: Ca-Gluconate does not have a
potassium-lowering effect
Potassium >5.5 mmol/l
GFR <15ml/min/1.73m2 GFR >15ml/min/1.73m2
Decreased renal
potassium excretion
Increased potassium load
→ Repeat samples if factitious hyperkalemia suspected
Aldosterone low Aldosterone high
Renin low Renin normal
Renin high
- Acute renal failure
- Chronic renal failure
- Drugs
- Supplementation (oral/iv)
- Potassium rich diet
- Blood transfusion
- Tumor lysis/ hemolysis
Hyporeninemic
hypoaldosteronism in:
￿ Interstitial nephritis
￿ Obstructive uropathies
￿D r u g s
￿ Diabetic nephropathy
￿ Primary hypoaldosteronism
￿ Congenital adrenal hyperplasia
￿D r u g s
￿ Addison‘s/congenital adrenal hypoplasia
￿ Post renal transplant
￿ Obstructive uropathy
￿ Sickle-cell nephropathy
￿D r u g s
￿ PHA type 1/ type 2
￿ Type 1 RTA
Calculating TTKG +/- adminstration of fludrocortisone may help in 
distinguishing patients who have mineralocorticoid deficiency versus
mineralocorticoid resistance (table 3).
*
*
Fig. 1 Diagnostic algorithm in hyperkalemia; adapted from Clinical Paediatric Nephrology. Used with permission from [40] RTA renal tubular
acidosis
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who are acidotic. In hemodialysis patients with
hyperkalemia it has only a moderate effect if given
as prolonged infusion [35]. NOTE: a rise in pH can
aggravate hypocalcemia.
Step 4: Increase potassium excretion
& Loop diuretics (furosemide) inhibit the inward
transport of potassium via NKCC2 channel in the
TAL. Even in chronic hemodialysis patients, treat-
ment with loop diuretics may be of value if the
patient has some residual renal function [36].
& Ion-exchange resins (containing calcium or sodium)
aim to keep enteral potassium from being resorbed.
More effective if given orally. Enemas should be
retained at least 30-60 min. [37]. Onset within 1-2
h, lasting 4-6 h.
& Renal replacement therapy (RRT) is the ultimate
measure in severe hyperkalemia. Hemodialysis
(HD) provides a substantially higher potassium
clearance (removal of 50-80 mmol of K
+ in a 4-
h session) than continuous forms of RRT. Contin-
uous veno-venous hemofiltration (CVVH) can
more satisfactorily provide long-term control of
potassium. Choice of method depends on local
circumstances and hemodynamics of the patients,
as critical ill patients will rarely tolerate HD
sessions [38].
In summary and conclusion, the effective and rapid
diagnosis and management of acute and chronic hyper-
kalemia in children, especially if renal function is impaired,
is clinically relevant and can be life-saving. In treatment of
moderate to severe hyperkalemia, the combination of
medications with different therapeutic approaches is usually
effective, and often methods of blood purification can be
avoided. In children with severe hyperkalemia and major
ECG abnormalities, conservative efforts should be initiated
immediately to stabilize the patient, but management
should include rapid facilitation of renal replacement
treatment.
Multiple-choice questions
(Answers appear following the reference list)
1) Which is the most important site of K
+ secretion in the
kidney?
a) proximal tubule
b) thin descending limb of loop of Henle
c) thick ascending limb of loop of Henle
d) distal tubule convolute
e) cortical collecting duct
2) Which drug does not cause hyperkalemia?
a) furosemide
b) amiloride
c) digoxin
d) labetalol
e) trimetoprim
3) Which of the following clinical conditions typically
causes hyperkalemia (answer true or false for (a)
through (e))
a) acute renal failure
b) acute myocardial infarction
c) rhabdomyolysis
d) hyperaldosteronism
e) Gordon’s syndrome
4) In managing a patient with severe hyperkalemia:
(answer true or false for (a) through (e))
a) first aspect of management is to establish the
underlying diagnosis
b) ECG may show QRS widening
c) the patient is invariably vomiting
d) in the short term, calcium gluconate may reduce
risk of arrhythmias
e) ventricular fibrillation and death may occur
5) The mode of action of salbutamol and glucose/insulin
is mediated by
a) an increase of renal elimination of potassium
b) a reduction of intestinal potassium intake
c) stabilization of membrane potential
d) an increase of potassium shift from extracellular
into intracellular compartment
e) hypoglycemia
6) In anuric patients, treatment of hyperkalemia
a) should include diuretics
b) by increasing elimination of potassium via the
gut (e.g., by enemas) may be an important option
c) is an infrequent problem
d) is always associated with cardiac symptoms
e) by shifting potassium into the intracellular depart-
ment is ineffective
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